the risk to 008 is the dropout rates due to a change in trial design and extension of monitoring periods that participants didn’t sign up for. And into that a suspension of the trial due to implementing a dosing range arm due to “feedback from the FDA” in H2 2021 when they were provided that feedback in Q1 2020. If you don’t think that’s a risk, it was clear in this forum that some participants were circumventing trial design by applying for SAS etc. within monitoring periods.
You heard it here first.
BTW - it’s only retail on the registrar. And going to the ECM through Bell Potter ain’t going to change that. Maybe Paul can thank the new overseas investors in Asia and the US again. but they were always mythical creatures that sold as soon as they could.
PAR Price at posting:
$1.99 Sentiment: Buy Disclosure: Held
(20min delay)